Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases Publisher



Azizi G1, 2 ; Abolhassani H2, 3 ; Asgardoon MH2 ; Rahnavard J1 ; Dizaji MZ4 ; Yazdani R5 ; Mohammadi J2, 6 ; Aghamohammadi A2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Laboratory Medicine, Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Karaj, Iran
  2. 2. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden
  4. 4. Department of Medical Genetics, Golestan University of Medical Sciences, Gorgan, Iran
  5. 5. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Department of Biomedical Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran

Source: Endocrine# Metabolic and Immune Disorders - Drug Targets Published:2016


Abstract

Immunoglobulin therapy represents a lifesaving intervention for many patients with primary immunodeficiency (PID). Antibody defects represent approximately half of the well-known PIDs requiring immunoglobulin replacement therapy. Following immunoglobulin therapy in PID patients, protection against serious upper and lower respiratory tract infections and pulmonary function improves which leads to an increase in the quality of life of these patients. Successful treatment of PID patients depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities of the patient, and the availability of the products. i¿½ 2016 Bentham Science Publishers.
Other Related Docs
9. Pulmonary Manifestations of Predominantly Antibody Deficiencies, Pulmonary Manifestations of Primary Immunodeficiency Diseases (2018)
16. Primary Antibody Deficiency in a Tertiary Referral Hospital: A 30-Year Experiment, Journal of Investigational Allergology and Clinical Immunology (2015)
22. Comparison of Common Monogenic Defects in a Large Predominantly Antibody Deficiency Cohort, Journal of Allergy and Clinical Immunology: In Practice (2019)
25. Evaluation of Pulmonary Complications in Patients With Primary Immunodeficiency Disorders, European Annals of Allergy and Clinical Immunology (2017)
26. Agammaglobulinemia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management, Endocrine# Metabolic and Immune Disorders - Drug Targets (2020)
28. T-Cell Abnormalities in Common Variable Immunodeficiency, Journal of Investigational Allergology and Clinical Immunology (2016)
31. Costs of Hospital Admission on Primary Immunodeficiency Diseases, Iranian Journal of Public Health (2017)
33. Potential Therapeutic Approach of Intravenous Immunoglobulin Against Covid-19, Allergy# Asthma and Clinical Immunology (2021)
41. Application of Flow Cytometry in Predominantly Antibody Deficiencies, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)